Ascendis Pharma announced Monday that it won FDA approval for its hypoparathyroidism drug, offering the small community of those suffering from insufficient levels of parathyroid …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.